WO2024023734 - MULTI-gRNA GENOME EDITING
National phase entry is expected:
Publication Number
WO/2024/023734
Publication Date
01.02.2024
International Application No.
PCT/IB2023/057589
International Filing Date
26.07.2023
Title **
[English]
MULTI-gRNA GENOME EDITING
[French]
ÉDITION GÉNOMIQUE MULTI-ARNG
Applicants **
BIT BIO LIMITED
Inventors
KLAPHOLZ, Benjamin
Priority Data
63/392,382
26.07.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3647 | |
| EPO | Filing, Examination, Granting | 41042 | |
| Japan | Filing, Examination, Granting | 3573 | |
| South Korea | Filing, Examination, Granting | 4948 | |
| USA | Filing, Examination, Granting | 15340 |
Total:
68,550
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Described herein are methods and compositions for performing genomic editing with multiple gRNAs, also called second-chance CRISPR/Cas9-mediated genome editing (second-chance editing, or scEditing). In certain aspects, the methods described herein comprise use of CRISPR/Cas9 to target genomic sites of interest at least twice sequentially, providing at least one additional opportunity or "second-chance" at each target polynucleotide sequence for the integration of a DNA cargo into by homology-directed repair (HDR) and are useful for increasing the accuracy of editing target polynucleotide sequences by CRISPR-mediated gene editing.[French]
La présente invention concerne des procédés et des compositions permettant de réaliser une édition génomique à l'aide de plusieurs ARNg, également appelée édition génomique médiée par CRISPR/Cas9 de seconde chance (édition de seconde chance, ou scEditing). Selon certains aspects, les procédés de la présente invention comprennent l'utilisation de CRISPR/Cas9 pour cibler des sites génomiques d'intérêt au moins deux fois successivement, fournissant au moins une opportunité supplémentaire ou "seconde chance" à chaque séquence de polynucléotide cible pour l'intégration d'une cargaison d'ADN dans celle-ci par la réparation dirigée par homologie (HDR) et sont utiles pour augmenter la précision de l'édition des séquences de polynucléotides cibles par l'édition génique médiée par CRISPR.